BioVendor Group is an international diagnostics company with its headquarters in Brno, Czech Republic.
BioVendor provides a broad range of IVD technologies and capabilities including, in-house development and manufacturing of immunoassays and molecular diagnostics for the clinical market, as well as a wide offering for the Life Sciences market.
The core of the portfolio consists of immunoassays in several formats, both single-test and multiplexed. The portfolio is focused on infectious serology, autoimmunity, endocrinology, and newly-discovered biomarkers.
Since its establishment in 1992, BioVendor has placed high importance on innovation and value brought to customers via providing diagnostics solutions. Recent examples include, fully automated ELISA platform, proprietary microarray solution, Next Generation Sequencing kits, and proprietary miRNA immunoassays.
BioVendor is committed to its strategy to grow internationally. BioVendor has an extensive track record of acquisitions including, TestLine Clinical Diagnostics (Czech Republic), ViennaLab Diagnostics (Austria), Oxford Biosystems (UK), and most recently in September 2017, DIAsource Immuno-Assays (Belgium).
BioVendor – Laboratorní Medicína a.s. (BioVendor LM) is a “mother company” of the corporate group composed of three divisions.
High quality BioVendor products are the result of long-term biotechnology R&D activities aimed at the international research and diagnostic community. BioVendor customers include world-renowned scientific institutions recognizing that BioVendor products meet the strictest quality and environmental criteria (certificates).